Enanta Pharmaceuticals Inc (ENTA)

Finanzdaten der Enanta Pharmaceuticals Inc-Aktie (ENTA)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	16.32%14.36	17.16	18.62	15.13	18.31
	13.80%22.13	19.44	-	23.81	27.21
Research and Development	13.80%22.13	19.44	-	23.81	27.21
Costs And Expenses	8.91%31.60	29.01	29.87	33.51	37.21
Depreciation and Amortization	1.99%1.19	1.21	1.23	1.28	1.21
Operating Income/Loss	45.43%-17.24	-11.85	-11.25	-18.39	-18.89
Nonoperating Income/Loss	80.93%-2.23	-1.23	-0.66	-0.28	0.67
Income/Loss From Continuing Operations Before Tax	48.77%-19.47	-13.08	-11.91	-18.67	-18.23
Income Tax Expense/Benefit	414.29%0.04	0.01	0.02	0.03	0.03
	48.96%-19.50	-13.09	-11.94	-18.70	-18.26
Attributable To Parent	48.96%-19.50	-13.09	-11.94	-18.70	-18.26
Basic Average Shares	0.17%29.09	29.04	28.75	-	21.38
Diluted Average Shares	0.17%29.09	29.04	28.75	-	21.38
Basic Earnings Per Share	48.89%-0.67	-0.45	-0.42	-	-0.85
Diluted Earnings Per Share	48.89%-0.67	-0.45	-0.42	-	-0.85